What is CAGR? What does CAGR table indicate for Sun Pharma Advanced Research Company Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Sun Pharma Advanced Research Company Ltd Stock Analysis

Small Cap

Evaluated by 1771 users | BSE: 532872 | NSE: SPARC |
Miscellaneous

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Sun Pharma Advanced Research Company Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	-63.23%	-1039.89%	-21.14%	17.97%	-31.77%	-71.29%	-95.66%	-134.42%	-59.51%	-179.38%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	58.4	29	87.3	167	156	161	181	78.3	183	76.8
Y-o-Y Gr. Rt.	-	-50.3%	201.2%	91.4%	-6.8%	3.6%	12.2%	-56.8%	133.7%	-58%
Adjusted EPS (Rs.)	-0.43	-3.42	-0.96	1.09	-1.66	-2.95	-4.87	-9.33	-5.51	-11.97
Y-o-Y Gr. Rt.	-	NA	NA	NA	-252.3%	NA	NA	NA	NA	NA
Book Value per Share (Rs.)	0.27	-3.16	4.52	5.82	4.18	1.21	6.41	3.71	11.3	-0.71
Adjusted Net Profit	-9.1	-72.6	-23	26.1	-39.6	-69.8	-120	-234	-144	-314
Net Op. Cash Flow (Rs. Cr.)	2.3	-69.5	-95.3	36.9	-41.2	-44.2	-128	-183	-172	-211
Debt to Cash Flow from Ops	2.87	-0.98	-0.85	0.14	-0.1	-1.26	-0.02	-0.01	-0.01	-0.32

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Sun Pharma Advanced Research Company Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Sun Pharma Advanced Research Company Ltd. should be analysed on a Standalone basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	3.1%	-13.2%	-24.9%	-58%
Adjusted EPS	NA	NA	NA	NA
Book Value per Share	-211.3	-170.2	-148	-106.3
Share Price	8.7%	-10.8%	-26.6%	20%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	-92.07	238.13	-109.78	21.04	-33.15	-106.06	-126.66	-136.59	-60.03	-225.95
Operating Profit Margin (%)	-11.36	-241.28	-18.98	20.06	-22.45	-38.97	-67.69	-309.98	-79.05	-397.68
Net Profit Margin (%)	-15.58	-250.59	-26.3	15.61	-25.44	-43.27	-66.45	-299.23	-78.94	-408.28
Debt to Equity	1.17	-1.02	0.75	0.04	0.04	1.94	0.02	0.02	0.01	-3.67
Working Capital Days	31	123	110	161	200	163	210	641	254	554
Cash Conversion Cycle	-78	-54	-27	-63	-80	-130	-170	-113	-272	-254

Management X-Ray

Shareholding Pattern

Entity	Percentage Holding
Promoters	68.46%
Institutions	3.07%
Non-Institutions	28.46%

Promoter's Holding & Share Pledging

Pledged ^*

2.03

3.14

3.05

1.32

1.90

0.75

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Sun Pharma Advanced Research Company Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Sun Pharma Advanced Research Company Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company. However, for specific investment actions please connect with your investment advisor.

2. Is current market price of Sun Pharma Advanced Research Company Ltd a good price to buy it?

The 5-year analysis of Sun Pharma Advanced Research Company Ltd's performance infers:

Sun Pharma Advanced Research Company Ltd earnings have grown by 0%, whereas share price has depreciated -10.8% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

3. What is Sun Pharma Advanced Research Company Ltd share price return in the past 10 years ?

We analysed the performance of Sun Pharma Advanced Research Company Ltd share prices over the last 10 years. Here is what we found out:

Sun Pharma Advanced Research Company Ltd share price has depreciated 6.3% annually over the past ten years.

About Company

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

2006: SPARC is founded in Vadodara, India
2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
2012: 1st NDA filed with USFDA for Elepsia XR
2012: Raised Rs. 200 crore through Rights Issue
2013: Filed NDA for Xelpros with USFDA
2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
2015: Entered into research collaboration in the field of Oncology with US University
2015: Launched Bevetex (PICS) in India
2016: Raised Rs. 250 crore through Rights Issue
2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications